Cassava Sciences Company Insiders
SAVA Stock | USD 3.98 0.15 3.92% |
Cassava Sciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Cassava Sciences stock suggests that vertually all insiders are extremely bullish at this time. Cassava Sciences employs about 29 people. The company is managed by 13 executives with a total tenure of roughly 32 years, averaging almost 2.0 years of service per executive, having 2.23 employees per reported executive.
Remi Barbier Chairman Chairman of the Board and Presidentident, CEO |
Cassava Sciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2023-08-23 | Sanford Robertson | Acquired 42000 @ 12.46 | View | ||
2023-08-21 | Richard Barry | Acquired 2668 @ 12 | View | ||
2023-03-06 | Richard Barry | Acquired 16190 @ 18.66 | View | ||
2022-08-23 | Richard Barry | Acquired 50622 @ 16.99 | View | ||
2022-08-12 | Sanford Robertson | Acquired 140000 @ 14.78 | View |
Monitoring Cassava Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cassava |
Cassava Sciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Cassava Sciences' future performance. Based on our forecasts, it is anticipated that Cassava will maintain a workforce of about 30 employees by December 2024.Cassava Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.456) % which means that it has lost $0.456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1098) %, meaning that it created substantial loss on money invested by shareholders. Cassava Sciences' management efficiency ratios could be used to measure how well Cassava Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.61. The current year's Return On Capital Employed is expected to grow to -0.73. At present, Cassava Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 7.9 M, whereas Total Assets are forecasted to decline to about 114.4 M.The current year's Common Stock Shares Outstanding is expected to grow to about 44 M, whereas Net Loss is projected to grow to (65.2 M).
Cassava Sciences Workforce Comparison
Cassava Sciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,226. Cassava Sciences maintains roughly 29.0 in number of employees contributing less than 1% to equities under Health Care industry.
Cassava Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cassava Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cassava Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cassava Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 3.4 | 17 | 5 | 443,085 | 170,390 |
2023-06-01 | 2.25 | 18 | 8 | 227,358 | 142,551 |
2023-03-01 | 1.0 | 4 | 4 | 95,983 | 12,281 |
2022-12-01 | 2.0 | 2 | 1 | 109,376 | 9,376 |
2022-09-01 | 4.0 | 4 | 1 | 141,159 | 2,802 |
2022-06-01 | 0.8 | 4 | 5 | 139,341 | 191,046 |
2022-03-01 | 2.0 | 2 | 1 | 9,339 | 4,024 |
2021-09-01 | 0.6667 | 2 | 3 | 5,602 | 7,348 |
2021-06-01 | 0.5 | 1 | 2 | 56,030 | 109,995 |
2021-03-01 | 0.6667 | 4 | 6 | 40,156 | 68,539 |
2018-12-01 | 0.5 | 1 | 2 | 50,000 | 512,660 |
2018-09-01 | 1.375 | 11 | 8 | 275,000 | 4,676,000 |
2014-12-01 | 7.0 | 7 | 1 | 1,250,000 | 5,000 |
2014-09-01 | 0.5 | 4 | 8 | 864,599 | 1,624,623 |
2014-06-01 | 3.5 | 14 | 4 | 1,579,951 | 302,095 |
2014-03-01 | 1.6667 | 5 | 3 | 180,167 | 102,727 |
2013-06-01 | 2.7778 | 25 | 9 | 1,602,087 | 318,230 |
2011-12-01 | 0.8333 | 5 | 6 | 66,820 | 422,000 |
2011-09-01 | 1.3333 | 8 | 6 | 1,127,671 | 704,501 |
2011-06-01 | 1.5455 | 17 | 11 | 1,537,081 | 1,345,876 |
2011-03-01 | 0.6667 | 4 | 6 | 109,971 | 184,939 |
2010-12-01 | 2.5 | 5 | 2 | 54,626 | 50,000 |
2010-09-01 | 0.6 | 9 | 15 | 638,000 | 143,360 |
2010-06-01 | 0.7826 | 18 | 23 | 156,743 | 273,479 |
2010-03-01 | 0.5 | 7 | 14 | 120,939 | 298,800 |
2009-12-01 | 0.1818 | 2 | 11 | 100,000 | 130,000 |
2009-09-01 | 0.3462 | 9 | 26 | 685,800 | 6,976,308 |
2009-06-01 | 0.0845 | 6 | 71 | 106,748 | 2,834,279 |
2009-03-01 | 0.0714 | 1 | 14 | 25,000 | 1,125,000 |
2008-12-01 | 0.4286 | 3 | 7 | 17,442 | 152,500 |
2008-09-01 | 1.5 | 9 | 6 | 445,574 | 150,000 |
2008-06-01 | 1.8333 | 11 | 6 | 938,163 | 150,000 |
2008-03-01 | 1.3636 | 15 | 11 | 255,500 | 223,400 |
2007-12-01 | 0.6667 | 4 | 6 | 81,219 | 150,000 |
2007-09-01 | 1.875 | 15 | 8 | 157,211 | 200,000 |
2007-06-01 | 1.25 | 15 | 12 | 1,010,270 | 210,000 |
2007-03-01 | 2.9231 | 38 | 13 | 990,761 | 172,000 |
2006-12-01 | 0.6923 | 9 | 13 | 255,323 | 181,000 |
2006-09-01 | 0.8182 | 9 | 11 | 82,664 | 173,000 |
2006-06-01 | 3.3 | 33 | 10 | 1,622,397 | 166,000 |
2006-03-01 | 0.0698 | 3 | 43 | 36,555 | 148,054 |
2005-12-01 | 7.0 | 21 | 3 | 285,964 | 35,000 |
2005-06-01 | 7.5 | 15 | 2 | 1,006,884 | 43,000 |
2004-12-01 | 2.0 | 2 | 1 | 18,093 | 25,000 |
2004-09-01 | 8.0 | 8 | 1 | 935,000 | 10,800 |
2003-09-01 | 9.0 | 9 | 1 | 559,504 | 94,985 |
Cassava Sciences Notable Stakeholders
A Cassava Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cassava Sciences often face trade-offs trying to please all of them. Cassava Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cassava Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Remi Barbier | Chairman of the Board and Presidentident, CEO | Profile | |
Christopher JD | Company VP | Profile | |
James MD | Chief Officer | Profile | |
Michael Zamloot | Senior Operations | Profile | |
Jaren Landen | Chief Officer | Profile | |
Michael PharmD | Senior Affairs | Profile | |
Lindsay Burns | Senior Neuroscience | Profile | |
Christopher Cook | Sr Counsel | Profile | |
Eric Schoen | Chief Officer | Profile | |
Nadav MD | Chief Director | Profile | |
Freda Nassif | Chief Officer | Profile | |
Richard Barry | Executive Board | Profile | |
George Thornton | Senior Technology | Profile |
About Cassava Sciences Management Performance
The success or failure of an entity such as Cassava Sciences often depends on how effective the management is. Cassava Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cassava management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cassava management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.64) | (0.61) | |
Return On Capital Employed | (0.77) | (0.73) | |
Return On Assets | (0.64) | (0.61) | |
Return On Equity | (0.71) | (0.67) |
Please note, the presentation of Cassava Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cassava Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cassava Sciences' management manipulating its earnings.
Cassava Sciences Workforce Analysis
Traditionally, organizations such as Cassava Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cassava Sciences within its industry.Cassava Sciences Manpower Efficiency
Return on Cassava Sciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 3.4M | |
Net Loss Per Executive | 7.5M | |
Working Capital Per Employee | 4M | |
Working Capital Per Executive | 8.9M |
Complementary Tools for Cassava Stock analysis
When running Cassava Sciences' price analysis, check to measure Cassava Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cassava Sciences is operating at the current time. Most of Cassava Sciences' value examination focuses on studying past and present price action to predict the probability of Cassava Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cassava Sciences' price. Additionally, you may evaluate how the addition of Cassava Sciences to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Transaction History View history of all your transactions and understand their impact on performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |